FDAnews
www.fdanews.com/articles/73136-collagenex-announces-agreement-to-promote-alcortin-and-novacort

CollaGenex Announces Agreement to Promote Alcortin and Novacort

June 8, 2005

CollaGenex Pharmaceuticals announced that it had entered into a Promotion and Cooperation Agreement with Primus Pharmaceuticals under which CollaGenex will promote Alcortin and Novacort to dermatologists in the United States. Alcortin (1 percent iodoquinol and 2 percent hydrocortisone) is a prescription topical antifungal steroid combination. Novacort (2 percent hydrocortisone acetate and 1 percent pramoxine HCl) is a prescription topical steroid and anesthetic. Both products contain a proprietary Biopeptide Aloe Complex which is designed to improve skin penetration and help reduce inflammation.

()a href="http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20050608005467&newsLang=en" target="_blank">Business Wire